Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in plasmodium falciparum malaria parasites in thies, senegal

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 3, Issue , 2013, Pages 135-142

  Ndiaye, Daouda ^a   Dieye, Baba ^a   Ndiaye, Yaye D ^a   Tyne, Daria Van ^b   Daniels, Rachel ^b   Bei, Amy K ^b   Mbaye, Aminata ^a   Valim, Clarissa ^b   Lukens, Amanda ^b   Mboup, Souleymane ^a   Ndir, Omar ^a   Wirth, Dyann F ^b   Volkman, Sarah ^b  

^a UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Dhfr dhps; Plasmodium falciparum; Pyrimethamine; Resistance

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; PYRIMETHAMINE PLUS SULFADOXINE;

ADULT; ARTICLE; CHILD; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; EX VIVO STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; POINT MUTATION; POPULATION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SENEGAL;

EID: 84882965977     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2013.07.001     Document Type: Article

References (62)

1. Alker A.P., Kazadi W.M., Kutelemeni A.K., Bloland P.B., Tshefu A.K., Meshnick S.R. Dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Trop. Med. Int. Health 2008, 13:1384-1391.
2. Andriantsoanirina V., Durand R., Pradines B., Baret E., Bouchier C., Ratsimbasoa A., Menard D. In vitro susceptibility to pyrimethamine of dhfr I164L single mutant Plasmodium falciparum. Malar. J. 2011, 10:283. 10.1186/1475-2875-10-283.
3. Aubouy A., Jafari S., Huart V., Migot-Nabias F., Mayombo J., Durand R., Bakary M., Le Bras J., Deloron P. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J. Antimicrob. Chemother. 2003, 53:43-49.
4. Baniecki M.L., Wirth D.F., Clardy J. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob. Agents Chemother. 2007, 51:716-723.
5. Basco L.K., De Pecoulas P.E., Wilson C.M., Le Bras J., Mazabraud A. Point mutations in the dihydrofolate reductase thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 1995, 69:135-138.
6. Basco L.K., Tahar R., Ringwald P. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob. Agents Chemother. 1998, 42:1811-1814.
7. Basco L.K., Tahar R., Keundjian A., Ringwald P. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine- pyrimethamine in patients with acute uncomplicated falciparum malaria. J. Infect. Dis. 2000, 182:624-628.
8. Bickii J., Basco L.K., Ringwald P. Assessment of three in vitro tests and an in vivo test for chloroquine resistance in Plasmodium falciparum clinical isolates. J. Clin. Microbiol. 1998, 36:243-247.
9. Boumbou-Moukoko E.C., Bogreau H., Briolant S., Pradines B., Rogier C. Molecular markers of Plasmodium falciparum drug resistance. Med. Trop. 2009, 69:606-612.
10. Bouyou-Akotet M.K., Mawili-Mboumbat D.P., Tchantchou T., Kombila M. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon. J. Antimicrob. Chemother. 2010, 65:438-441.
11. Brooks D.R., Wang P., Read M., Watkins W.M., Sims P.F., et al. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 1994, 224:397-405.
12. Bwijo B., Kaneko A., Takechi A., Zungu I.L., Moriyama Y., et al. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first first line treatment in Malawi. Acta Trop. 2003, 85:363-373.
13. Bzik D.J., Li W.B., Hon T., Inselburg J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc. Natl. Acad. Sci. USA 1987, 84:8360-8364.
14. Cowman A.F., Morry M.J., Biggs B.A., Cross G.A., Foote S.J. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 1988, 85:9109-9113.
15. Daniels R., Ndiaye D., Wall M., McKinney J., Sene P.D., Sabeti P.C., Volkman S., Mboup S., Wirth D.F. Rapid, field-deployable method for genotyping and discovery of single-nucleotide polymorphisms associated with drug resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 2012, 56(6):2976-2986.
16. Desjardins R.E., Canfield C.J., Haynes J.D., Chulay J.D. Quantitative assessment of antimalarial activity in vitro by a semi automated microdilution technique. Antimicrob. Agents Chemother. 1979, 16:710-718.
17. Djaman J.A., Mazabraud A., Basco L. sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Cote d'Ivoire. Ann. Trop. Med. Parasitol. 2007, 101(2):103-112.
18. Dicko A., Sagara I., Djimbde A.A., Toure S.O., Traore M., Dama S., Diallo A.I., Barry A., Dicko M., Coulibaly O.M., Rogier C., De Sousa A., Doumbo O.K. Molecular markers of resistance to sulfadoxine-pyriemethamine one year after implementiion of intermittent preventive treatment of malaria in infants in Mali. Malar. J. 2010, 10(9):9. http://dx.doi.org/10.1186/1475-2875-9-9.
19. Faye B., Ndiaye M., Ndiaye J.L., Annie A., Tine R.C., Lo A.C., Ndiaye M., Sow D., De Sousa A., Gaye O. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol. Res. 2011, 109:133-138.
20. Faye O., Gaye O., Fontenille D., et al. Comparison of the transmission of malaria in two epidemiological patterns in Senegal: the Sahel border and the Sudan-type savanna. Dakar Med. 1995, 40:1-7.
21. Foote S.J., Galatis D., Cowman A.F. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differs from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA 1990, 87:3014-3017.
22. Griffin J.T., Cairns M., Ghani A.C., Roper C., Schellenberg D., Carneiro I., Newman R.D., et al. Protective efficacy of Intermittent Preventive Treatment of Malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. Plos One. 2010, 5(9):e12618.
23. Happi C.T., Gbotosho G.O., Folarin O.A., Akinboye D.O., Yusuf B.O., Ebong O.O., Sowunmi A., Kyle D.E., Milhous W., Wirth D.F., Oduola A.M. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005, 95:183-193.
24. Henry M., Diallo I., Bordes J., Ka S., Pradines B., Diatta B., Mbaye P.S., Sane M., Thiam M., Gueye P.M., Wade B., Touze J.E., Debonne J.M., Rogier C., Fusai T. Urban malaria in Dakar, Senegal. Am. J. Trop. Med. Hyg. 2006, 75(1):146-151.
25. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., Plowe C.V. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 2002, 185:380-388.
26. Kurth F., Pongratz P., Belard S., Mordmuller B., Kremsner P.G., Ramharter M. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malar. J. 2009, 23(8):79. 10.1186/1475-2875-8-79.
27. Laufer M.K., Djimbde A.A., Plowe C.C. Monitoring and dettering drug resistance malaria in the area of combination therapy. Am. J. Trop. Med. Hyg. 2007, 77(Suppl. 6):160-169.
28. Malisa A.L., Pearce R.J., Abdulla S., Mshinda H., Kachur P.S., Bloland P., Roper C. Drug coverage in treatment of malaria and the consequence for resistance evolution-evidence from the use of sulfadoxine/pyrimethamine. Malar. J. 2010, 9:190. 10.1186/1475-2875-9-190.
29. McCollum A.M., Schneider K.A., Griffing S.M., Zhou Z., et al. Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. Malar. J. 2012, 11:77. 10.1186/1475-2875-11-77.
30. Menard D., Yapou F., Manirakiza A., Djalle D., Matsika-Claquin M.D., Talarmin A. Polymorphism in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. Am. J. Trop. Med. Hyg. 2006, 75(3):381-387.
31. Mombo-Ngoma G., Oyakhirome S., et al. High prevalence of dhfr triple mutatnt and correlation with high rates of sulfadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malar. J. 2011, 10:123. 10.1186/1475-2875-10-123.
32. Mugittu K., Ndejembi M., Malisa A., Lemnge M., Premji Z., Mwita A., Nkya W., Kataraihya J., Abdulla S., Beck H.P., Mshinda H. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am. J. Trop. Med. Hyg. 2004, 71:696-702.
33. Mula P., Fernandez-Martinez A., De Lucio A., Ramos J.M., Reyes F., Gonzalez V., Benito A., Berzosa P. Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at rural hospital in southern Ethiopia. Malar. J. 2011, 10:214. 10.1186/1475-2875-10-214.
34. Naidoo I., Ropper C. Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology 2011, 138(12):1469-1479.
35. Ndiaye D., Daily J.P., Sarr O., Ndir O., Gaye O., Mboup S., Wirth D.F. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop. Med. Int. Health 2005, 10(11):1176-1179.
36. Ndiaye D., Daily J.P., Sarr O., Ndir O., Gaye O., Mboup S., Roper C., Wirth D.F. Defining the origin of Plasmodium falciparum resistant dhfr isolates in Senegal. Acta Trop. 2006, 99(1):106-111.
37. Ndiaye D., Patel V., et al. A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials increased sensitivity of P. falciparum to chloroquine in Senegal. Am. J. Trop. Med. Hyg. 2010, 82(2):228-230.
38. Nzila-Mounda A., Mberu E.K., Sibley C.H., Plowe C.V., Winstanley P.A., Watkins W.M. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 1998, 42:164-169.
39. Omar S.A., Adagu I.S., Warhurst D.C. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:315-319.
40. Peterson D.S., Walliker D., Wellems T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA 1988, 85:9114-9118.
41. Peterson D.S., Milhous W.K., Wellems T.E. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. USA 1990, 87:3018-3022.
42. Petersen D.S., Di Santi S.M., Povoa M., Calvosa V.S., Do Rosario V.E., Wellems T.E. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am. J. Trop. Med. Hyg. 1991, 45(4):492-497.
43. Picot S., Olliaro P., De Monbrison F., Bienvenu A.L., Price R.N., Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 2009, 8:89. 10.1186/1475-2875-8-89.
44. Raman J., Little F., Roper C., Kleinschmidt I., Cassam Y., Maharaj R., Barnes K.I. Five years of large -scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo province, southern Mozambique. Am. J. Trop. Med. Hyg. 2010, 82(5):788-794.
45. Reeder J.C., Rieckmann K.H., Genton B., Lorry K., Wines B., Cowman A.F. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am. J. Trop. Med. Hyg. 1996, 55:209-213.
46. Sirawaraporn W., Sathitkul T., Sirawaraporn R., Yuthavong Y., Santi D.V. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. USA 1997, 94:1124-1129.
47. Smilkstein M., Sriwilaijaroen N., Kelly J.X., Wilairat P., Riscoe M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 2004, 48:1803-1806.
48. Staedke S.G., Sendagire H., Lamola S., Kamya M.R., Dorsey G., et al. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health 2004, 9:624-629.
49. Talisuna A.O., Nalunkuma-Kazibwe A., Langi P., Mutabingwa T.K., Watkins W.W., Marck E.V., Egwang T.G., D'Alessandro U. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Uganda children with uncomplicated falciparum malaria. Infect. Genet. Evol. 2004, 4:321-327.
50. Thomas S.M., Ndir O., Dieng T., et al. In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 poly-morphisms in Plasmodium falciparum isolates from Senegal. Am. J. Trop. Med. Hyg. 2002, 66:474-480.
51. Trape J.F., Lefebvre-Zante E., Legros F., et al. Vector density gradients and the epidemiology of urban malaria in Dakar, Sengal. Am. J. Trop. Med. Hyg. 1992, 147:181-189.
52. Triglia T., Cowman A.F. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 1994, 91:7149-7153.
53. Triglia T., Menting J.G., Wilson C., Cowman A.F. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 1997, 94:13944-13949.
54. Warhurst D.C. A molecular marker for chloroquine resistant falciparum malaria. N. Engl. J. Med. 2001, 344:299-302.
55. Warsame M., Wernsdorfer W.H., Payne D., Bjorkman A. Susceptibility of Plasmodium falciparum in vitro to chloroquine, mefloquine, quinine and sulfadoxine/pyrimethamine in Somalia: relationships between the responses to the different drugs. Trans. R. Soc. Trop. Med. Hyg. 2001, 85:565-569.
56. WHO, 2004. A strategic framework for Malaria Prevention and Control during Pregnancy in the African Region. Brazzaville, World Health Organization Regional Office for Africa, AFR/MAL/04/01.
57. WHO, 2010. Guidelines for the treatment of malaria. 1. Malaria - Drug Therapy. 2. Malaria - Diagnosis. 3. Antimalarials - Administration and Dosage. 4. Drug Therapy, Combination. 5. Guidelines, second ed. World Health Organization.
58. WHO, 2012. Malaria report. Global Malaria Programme World Health Organization 20, Avenue Appia CH-1211, Geneva 27. Available from:, e-mail:. mailto:infogmpatwho.int.
59. WHO Global Malaria Programme, 2012. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum Malaria Control in Highly Seasonal Transmission Areas of the Sahel Sub-region in Africa.
60. WHO, 2010. Focus on Senegal. Roll Back Malaria Progress and Impact Series, vol. 4. Geneva, pp. 1-56.
61. Yusuf R.U., Omar S.A., Ngure R.M. The effect of point mutations in dihydrofolate reductase genes and the multidrug resistance gene 1-86 on treatment of falciparum malaria in Sudan. J. Infect. Dev. Ctries. 2010, 4(2):61-69.
62. Zakeri S., Farahani M.S., Afsharpad M., Salehi M., Raeisi A., Djadid N.D. High Prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine. Int. J. Infect. Dis. 2010, 14S:e123-e128.